You have accessMine the Stability of the G2/M Checkpoint to Break Down Acute Lymphoblastic Leukemia Defenses Against Antineoplastic Drugs
Andrea Ghelli Luserna di Rorà(Fondazione Pisa), Yen Timothy, Chiara Ronchini(European Institute of Oncology), Cristina Papayannidis(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Neil Beeharry(Johnson & Johnson (United States)), Ilaria Iacobucci(St. Jude Children's Research Hospital), Antonella Padella(University of Bologna), Giovanni Martinelli(University of Bologna), Enrica Imbrogno(University of Bologna), Valentina Robustelli(University of Bologna), Maria Vittoria Verga Falzacappa(University of Trieste), Anna Ferrari(University of Bologna)
Unknown
January 1, 2016
Cited by 0
Related Papers
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
|New England Journal of Medicine|2005|644
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia
|Nature Genetics|2019|627